CheckMate 436: Extended Follow-Up from the Phase 2 Study Investigating Nivolumab Plus Brentuximab Vedotin (BV) for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (R/R PMBL)-MedSci.cn

CheckMate 436: Extended Follow-Up from the Phase 2 Study Investigating Nivolumab Plus Brentuximab Vedotin (BV) for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (R/R PMBL)

Zinzani, PL; Santoro, A; Gritti, G; Brice, P; Barr, P; Cunningham, D; Kline, J; Johnson, N; Mehta-Shah, N; Fanale, M; Francis, S; Moskowitz, A

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021; 21 (): S398

科室
- - 订阅+
  - 更多科室
工具
服务